PubMed:18674790 / 753-1015 JSONTXT

{"project":"LitCoin-sentences","denotations":[{"id":"T6","span":{"begin":0,"end":262},"obj":"Sentence"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}

{"project":"LitCoin-entities-OrganismTaxon-PD","denotations":[{"id":"T7","span":{"begin":197,"end":201},"obj":"OrganismTaxon"}],"attributes":[{"id":"A7","pred":"db_id","subj":"T7","obj":"NCBItxid:10118"},{"id":"A8","pred":"db_id","subj":"T7","obj":"NCBItxid:10116"},{"id":"A9","pred":"db_id","subj":"T7","obj":"NCBItxid:10114"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}

{"project":"LitCoin-entities","denotations":[{"id":"5401","span":{"begin":20,"end":31},"obj":"ChemicalEntity"},{"id":"5402","span":{"begin":104,"end":118},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5403","span":{"begin":120,"end":139},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5404","span":{"begin":141,"end":146},"obj":"ChemicalEntity"},{"id":"5405","span":{"begin":186,"end":191},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5406","span":{"begin":193,"end":195},"obj":"DiseaseOrPhenotypicFeature"},{"id":"5407","span":{"begin":197,"end":201},"obj":"OrganismTaxon"},{"id":"5408","span":{"begin":236,"end":261},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A21","pred":"db_id","subj":"5401","obj":"MESH:D004317"},{"id":"A22","pred":"db_id","subj":"5402","obj":"MESH:D066126"},{"id":"A23","pred":"db_id","subj":"5403","obj":"MESH:D006331"},{"id":"A24","pred":"db_id","subj":"5404","obj":"MESH:D008055"},{"id":"A25","pred":"db_id","subj":"5405","obj":"MESH:D009765"},{"id":"A26","pred":"db_id","subj":"5406","obj":"MESH:D009765"},{"id":"A27","pred":"db_id","subj":"5407","obj":"NCBITaxon:10116"},{"id":"A28","pred":"db_id","subj":"5408","obj":"MESH:D007674"},{"id":"A29","pred":"db_id","subj":"5408","obj":"MESH:D056486"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}

{"project":"LitCoin_Mondo","denotations":[{"id":"T1","span":{"begin":245,"end":252},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A1","pred":"mondo_id","subj":"T1","obj":"0002251"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T8","span":{"begin":186,"end":191},"obj":"GeneOrGeneProduct"},{"id":"T9","span":{"begin":193,"end":195},"obj":"GeneOrGeneProduct"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T18","span":{"begin":17,"end":19},"obj":"GeneOrGeneProduct"},{"id":"T19","span":{"begin":147,"end":159},"obj":"GeneOrGeneProduct"},{"id":"T20","span":{"begin":186,"end":191},"obj":"GeneOrGeneProduct"},{"id":"T21","span":{"begin":193,"end":195},"obj":"GeneOrGeneProduct"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T7","span":{"begin":104,"end":118},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":120,"end":139},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":186,"end":191},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":193,"end":195},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":253,"end":261},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A7","pred":"originalLabel","subj":"T7","obj":"D066126"},{"id":"A8","pred":"originalLabel","subj":"T8","obj":"DISEASE"},{"id":"A9","pred":"originalLabel","subj":"T9","obj":"DISEASE"},{"id":"A10","pred":"originalLabel","subj":"T10","obj":"DISEASE"},{"id":"A11","pred":"originalLabel","subj":"T11","obj":"DISEASE"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T7","span":{"begin":104,"end":118},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":120,"end":139},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":186,"end":191},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":193,"end":195},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":236,"end":261},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A7","pred":"ID:","subj":"T7","obj":"D066126"},{"id":"A8","pred":"ID:","subj":"T8","obj":"DISEASE"},{"id":"A9","pred":"ID:","subj":"T9","obj":"DISEASE"},{"id":"A10","pred":"ID:","subj":"T10","obj":"DISEASE"},{"id":"A11","pred":"ID:","subj":"T11","obj":"DISEASE"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T7","span":{"begin":104,"end":118},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T8","span":{"begin":120,"end":139},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":186,"end":191},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T10","span":{"begin":193,"end":195},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T11","span":{"begin":236,"end":261},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A7","pred":"#label","subj":"T7","obj":"D066126"},{"id":"A8","pred":"#label","subj":"T8","obj":"DISEASE"},{"id":"A9","pred":"#label","subj":"T9","obj":"DISEASE"},{"id":"A10","pred":"#label","subj":"T10","obj":"DISEASE"},{"id":"A11","pred":"#label","subj":"T11","obj":"DISEASE"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T18","span":{"begin":20,"end":31},"obj":"ChemicalEntity"}],"attributes":[{"id":"A18","pred":"ID:","subj":"T18","obj":"D004317"},{"id":"A19","pred":"ID:","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_64816"},{"id":"A20","pred":"ID:","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_28748"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T4","span":{"begin":197,"end":201},"obj":"OrganismTaxon"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T18","span":{"begin":20,"end":31},"obj":"ChemicalEntity"},{"id":"T86539","span":{"begin":236,"end":261},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T91619","span":{"begin":193,"end":195},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T65804","span":{"begin":186,"end":191},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T20828","span":{"begin":120,"end":139},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T90021","span":{"begin":104,"end":118},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T36993","span":{"begin":197,"end":201},"obj":"OrganismTaxon"}],"attributes":[{"id":"A20","pred":"ID:","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_28748"},{"id":"A19","pred":"ID:","subj":"T18","obj":"http://purl.obolibrary.org/obo/CHEBI_64816"},{"id":"A18","pred":"ID:","subj":"T18","obj":"D004317"},{"id":"A63011","pred":"#label","subj":"T86539","obj":"DISEASE"},{"id":"A67371","pred":"#label","subj":"T91619","obj":"DISEASE"},{"id":"A22182","pred":"#label","subj":"T65804","obj":"DISEASE"},{"id":"A5063","pred":"#label","subj":"T20828","obj":"DISEASE"},{"id":"A21371","pred":"#label","subj":"T90021","obj":"D066126"}],"text":"A LD(10) dose (8 mg doxorubicin/kg, ip) administered on day 43 of the HFD feeding regimen led to higher cardiotoxicity, cardiac dysfunction, lipid peroxidation, and 80% mortality in the obese (OB) rats in the absence of any significant renal or hepatic toxicity."}